According to the new agreement, BioFocus, Galapagos’ service division, will use its SilenceSelect platform to deliver validated targets to Ono. Ono works to find modulators for the targets and generate novel drug candidates.
The companies have kept the financial details of the agreement confidential.
BioFocus managing director and Galapagos Services SVP Chris Newton said, "The start of a new collaboration one year after the first one is testament to our target discovery platform and the strength of our partnership."
BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capability in neurodegenerative diseases, inflammatory diseases and delivering candidates against rare and neglected diseases.